- Home
- NBXG vs MESO Comparison
NBXG vs MESO Comparison
Compare NBXG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- MESO
- Stock Information
- Founded
- NBXG 2021
- MESO 2004
- Country
- NBXG United States
- MESO Australia
- Employees
- NBXG N/A
- MESO N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBXG Finance
- MESO Health Care
- Exchange
- NBXG Nasdaq
- MESO Nasdaq
- Market Cap
- NBXG 1.0B
- MESO 1.1B
- IPO Year
- NBXG N/A
- MESO N/A
- Fundamental
- Price
- NBXG $13.17
- MESO $10.18
- Analyst Decision
- NBXG
- MESO Strong Buy
- Analyst Count
- NBXG 0
- MESO 4
- Target Price
- NBXG N/A
- MESO $11.50
- AVG Volume (30 Days)
- NBXG 243.7K
- MESO 214.1K
- Earning Date
- NBXG 01-01-0001
- MESO 08-28-2024
- Dividend Yield
- NBXG 10.25%
- MESO N/A
- EPS Growth
- NBXG N/A
- MESO N/A
- EPS
- NBXG N/A
- MESO N/A
- Revenue
- NBXG N/A
- MESO $5,902,000.00
- Revenue This Year
- NBXG N/A
- MESO $66.05
- Revenue Next Year
- NBXG N/A
- MESO $348.27
- P/E Ratio
- NBXG N/A
- MESO N/A
- Revenue Growth
- NBXG N/A
- MESO N/A
- 52 Week Low
- NBXG $9.31
- MESO $1.61
- 52 Week High
- NBXG $12.23
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- NBXG 54.86
- MESO 54.47
- Support Level
- NBXG $12.93
- MESO $10.00
- Resistance Level
- NBXG $13.17
- MESO $10.98
- Average True Range (ATR)
- NBXG 0.18
- MESO 0.59
- MACD
- NBXG -0.01
- MESO 0.05
- Stochastic Oscillator
- NBXG 58.82
- MESO 46.61
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.